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Objective. To describe obstetricians’ perspectives related to tetanus-diphtheria-acellular pertussis (Tdap) vaccination of mothers
and other adults in close contact with infants. Methods. Mail survey of national random sample of 400 obstetricians . Results.
Response rate was 54%. Most respondents would likely recommend Tdap for women during the postpartum hospital stay (78%)
or during pregnancy (69%) if a national recommendation was issued. Expected barriers were knowing the date of patients’ most
recent Td booster (74%) and patient resistance (46%). Most felt that obstetricians have a role in promoting and administering
Tdap vaccine to adults other than mothers likely to come in close contact with infants. Conclusion. Obstetricians are likely to agree
with the recent provisional US recommendation to administer Tdap to postpartum mothers and other adults expected to come in
close contact with infants. Obstetricians would also be likely to support a potential recommendation to administer Tdap during
pregnancy. Barriers to adoption of new Tdap vaccine recommendations should be monitored.
Copyright © 2006 Sarah J. Clark et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Pertussisisahighlycommunicableinfectionthatcarriessub-
stantial morbidity. The incidence of reported pertussis is in-
creasing in all age groups, with over 25000 cases reported to
the Centers for Disease Control and Prevention (CDC) in
2004 [1]. Infants, especially those who have not yet received
the routine three-dose primary series of diphtheria-tetanus-
pertussis vaccine, are particularly vulnerable to severe com-
plications and death from pertussis [2], and often become
infected through exposure to infected adults [3].
The ability to vaccinate adults against pertussis would
reduce morbidity among adults and help prevent transmis-
sion to vulnerable infants. Prior to 2005, no pertussis vaccine
was licensed in the United States for adults. In June 2005,
the US Food and Drug Administration (FDA) approved li-
censure for a combination tetanus-diphtheria-acellular per-
tussis booster vaccine (Tdap, ADACEL, sanoﬁ pasteur) for
one-time use as a single dose in persons 11–64 years of age.
Tdap has been shown to be safe and immunogenic in men
andnonpregnantwomen;nocontrolledtrialshavebeencon-
ducted to examine the safety and immunogenicity of Tdap
during pregnancy or its eﬀects on the infant immune re-
sponse.
Following licensure, the US Advisory Committee on Im-
munization Practices (ACIP), with liaison representation
from the American College of Obstetricians and Gynecolo-
gists (ACOG) and other partners, deliberated regarding rec-
ommendations for use of this new vaccine in adults. In par-
ticular, the ACIP discussed targeting a Tdap recommenda-
tion to women and other adults likely to come in close con-
tact with infants.
Because obstetricians are an important direct link to
women who are or will soon be in close contact with infants,
we undertook a study to explore their perspectives regarding
potential administration of Tdap to postpartum mothers or
pregnant women, and to other adults expected to come in
close contact with infants. These data were provided to the
ACIP in October 2005.
METHODS
Sample
A national random sample of 400 obstetricians was drawn
from the AMA Masterﬁle through an AMA-endorsed2 Infectious Diseases in Obstetrics and Gynecology
contracted vendor (Medical Marketing Service, Inc.). The
AMA Masterﬁle, a database of all licensed US physicians,
is the most comprehensive physician listing in the United
States, and includes both AMA members and nonmembers.
The sampling frame included all allopathic and osteopathic
physicians self-described as an obstetrician/gynecologist, in
oﬃce-based direct patient care. Excluded were physicians
with any subspecialty board listing, physicians 70 years of
age or older, resident physicians, and physicians practicing
at federal government (ie, Veterans Aﬀairs, military) medical
facilities.ThestudywasapprovedbytheInstitutionalReview
Board of the University of Michigan Medical School, with a
waiver of documentation of informed consent.
Surveyinstrument
The study team developed a one-page, 6-item survey instru-
ment, accompanied by a one-page “Fact Sheet” regarding
pertussis disease and the recently licensed Tdap vaccine. To
verify eligibility, a screening item asked whether the respon-
dent currently provides obstetric care. Survey items included
current approach to administering inﬂuenza and measles-
mumps-rubella (MMR) vaccines; likelihood of recommend-
ing Tdap vaccine during pregnancy and during the postpar-
tum hospital stay, if recommended by ACIP/ACOG; barriers
to administering Tdap vaccine to obstetric patients; and per-
ceived responsibility for promoting or administering Tdap
vaccine to adults expected to come in close contact with
young infants.
The survey instrument and Fact Sheet were pilot tested
with a convenience sample of obstetricians to ensure clarity
andeaseofadministration.Reﬁnementsweremadebasedon
pilot test feedback.
Surveyadministration
To meet the timeframe of the ACIP workgroup, only one
mailing of the survey was ﬁelded, in August 2005. Survey
packetscontainedacoverletterexplainingthepurposeofthe
study, the Fact Sheet and survey form, and a $5 cash incen-
tive.
Dataanalysis
Initial univariate frequencies were generated for each vari-
able. Chi-square analyses were performed to explore associa-
tions between variables. A two-tailed α level of .05 was used
as the threshold for statistical signiﬁcance. All analyses were
conducted using SAS version 8.2 (SAS, Inc., Cary, NC).
RESULTS
Samplecharacteristics
Of the 400 obstetricians in the study sample, 5 were ex-
cludedbecausemailingmaterialswerereturnedasundeliver-
able. Surveys were returned by 212 respondents, for an over-
all response rate of 54%. Of the 212 respondents, 29 were
ineligible because they do not provide obstetric care, leav-
ing 183 surveys eligible for analysis. With regard to demo-
graphic characteristics of this group, 79% are board-certiﬁed
inobstetrics-gynecology;40%arefemale;43%aremorethan
50 years of age; and 47% work in a multispecialty practice
site.
Currentapproachtoadministeringvaccinesto
obstetricpatients
Most respondents (87%) reported that they routinely ad-
minister MMR vaccine to rubella nonimmune women im-
mediately after delivery (postpartum hospital stay); 4% re-
ported sometimes;a n d9 %r e p o r t e drarely/never administer-
ing MMR vaccine. In comparison, 61% reported routinely
administering inﬂuenza vaccine to pregnant patients; 19%
reported sometimes; and 20% reported rarely/never admin-
istering inﬂuenza vaccine during pregnancy.
LikelihoodofrecommendingTdapvaccinefor
obstetricpatients
Overall, 78% of respondents agree or strongly agree that they
would likely recommend Tdap vaccine for women immedi-
ately after delivery (in the postpartum hospital stay) if rec-
ommended by ACIP/ACOG. A lower proportion (69%) of
respondents agree or strongly agree thattheywouldlikelyrec-
ommend Tdap vaccine for women during pregnancy if rec-
ommended by ACIP/ACOG. For both questions, only 9%
of respondents strongly disagree that they would recommend
Tdap vaccine. Respondents’ extent of agreement with these
statements did not diﬀer by their current approach to ad-
ministering inﬂuenza vaccine or MMR vaccine.
AnticipatedbarrierstoTdapvaccinationof
obstetricpatients
Under the assumption of an ACIP/ACOG recommenda-
tion for Tdap vaccination of postpartum and/or pregnant
women, the most commonly expected major barrier to vac-
cination was knowing the date of a patient’s most recent Td
booster (74% of respondents). Nearly half of respondents
(46%)feltpatientreluctanceorrefusalwouldbeamajor bar-
rier, while 19% reported that having other priorities during
obstetric visits would be a barrier. With regard to an open-
ended question about other barriers, 14% of respondents
noted cost-related issues (eg, reimbursement, vaccine cost)
as a potential barrier.
Inbivariateanalyses,anticipatedbarrierscitedbyrespon-
dents were not associated with their likelihood of recom-
mending Tdap vaccine to postpartum or pregnant women.
PerspectivesonTdapvaccineforadultsinclose
contactwithinfants
Respondents were asked which physician group(s) should
bear responsibility for promoting and administering Tdap
vaccine to adults likely to come in close contact with infantsSarah J. Clark et al 3
Table 1: Diﬀerences in obstetricians’ perceived responsibility for promoting or administering Tdap vaccine to adults in close contact with
infants (P value compares responses of agree/strongly agree versus neutral/disagree/strongly disagree).
Proportion of respondents who agree that obstetricians have responsibility for
Promoting Tdap vaccine among
adults in close contact with infants
Administering Tdap vaccine to
adults in close contact with infants
I would likely recommend Tdap vaccine
for women during pregnancy if
recommended by ACIP/ACOG
Agree/strongly agree 77% <. 001 75% <. 001
Neutral/disagree/strongly disagree 50% — 60% —
I would likely recommend Tdap vaccine
for women immediately after delivery if
recommended by ACIP/ACOG
Agree/strongly agree 85% <. 05 83% <. 05
Neutral/disagree/strongly disagree 59% — 68% —
≤ 6 months of age, assuming that an ACIP/ACOG recom-
mendation would target this group. With regard to promot-
ing Tdap vaccination, respondents perceived a shared re-
sponsibility among obstetricians (72%), adult primary care
providers (81%), pediatricians (68%), and public health
providers (60%). With regard to administering Tdap vac-
cine to adults likely to come in close contact with infants
≤ 6 months of age, respondents perceived a greater respon-
sibility for adult primary care providers (89%) compared
with obstetricians (62%), pediatricians (24%), and public
healthproviders(61%).Inbivariateanalyses,thosewhowere
likely to recommend Tdap vaccine to postpartum or preg-
nant women, if recommended by ACIP/ACOG, were more
likely to perceive themselves as having a role in both promot-
ing and administering Tdap vaccine to other adults likely to
come in close contact with infants (Table 1).
DISCUSSION
In October 2005 the ACIP, with liaison representation from
ACOG and other partners, voted to recommend that adults
19–64 years receive a single dose of Tdap vaccine to replace
their next Td dose [4]. ACIP also voted to recommend that
adults in close contact, or anticipating close contact, with
an infant < 12 months of age (eg, parents, grandparents,
childcare providers, and health care workers) receive a dose
of Tdap as soon as feasible, if they have not previously re-
ceived Tdap. The recommendation suggests an interval of
2 years since the most recent Td, although shorter intervals
may be used. In addition, women planning a pregnancy and
women in the immediate postpartum period are advised to
receiveTdapiftheyhavenotpreviouslydoneso.Pregnancyis
not considered a contraindication to Tdap vaccination, and
guidance on the use of Tdap during pregnancy was still un-
der consideration by ACIP and ACOG.
Results of this study, conducted prior to these recom-
mendations, demonstrate that obstetricians will likely sup-
port Tdap vaccination of obstetric patients if recommended
by ACIP/ACOG. There appeared to be a slight preference
for vaccination in the immediate postpartum period; still,
the majority of respondents felt they would recommend
vaccination during pregnancy, if endorsed in the future by
ACIP/ACOG. This sentiment is consistent with prior re-
search demonstrating that most obstetricians recommend
inﬂuenza vaccination during pregnancy [5]. Note that the
Fact Sheet included with this survey did state that there is
no comprehensive information on the beneﬁts and risks of
Tdap vaccination during pregnancy, as is true for other rec-
ommended vaccines [6].
The factors inﬂuencing obstetricians’ perceived likeli-
hood of recommending Tdap to pregnant or postpartum
women,ifrecommendedbyACIP/ACOG, areunclear.While
it might be assumed that obstetricians who routinely admin-
ister MMR and inﬂuenza vaccines would be more inclined to
consider themselves likely to recommend Tdap vaccine, we
did not ﬁnd that to be true in this study. In addition, per-
ceived barriers to Tdap administration were not associated
with predicted likelihood of recommending Tdap. Prior re-
search has shown ACOG endorsement to be an important
inﬂuence on obstetrician decisions about vaccination [7]. It
is likely that practicing obstetricians expect the members of
ACIP and ACOG to craft the most appropriate Tdap recom-
mendations after reviewing the available evidence.
Practice patterns for other vaccines can provide impor-
tant clues to the uptake of new vaccines. Practices related to
MMR vaccine for rubella nonimmune women in the post-
partum period may provide the best analogy to the Tdap
postpartumvaccinationrecommendation.Inourstudy,87%
ofobstetriciansreportedthattheyroutinelyadministerMMR
vaccine to postpartum mothers as indicated. However, logis-
tical barriers to postpartum MMR vaccination remain; pre-
vious studies have shown that a signiﬁcant proportion of ob-
stetric practices do not stock MMR [7] and that a signiﬁcant
proportion of hospitals do not have rubella immunization4 Infectious Diseases in Obstetrics and Gynecology
programsforpostpartumwomen[8].AdoptionofTdapvac-
cine by obstetricians may be hampered by these same barri-
ers.
This study identiﬁed several barriers to Tdap vaccina-
tion for obstetric patients. Three quarters of respondents
felt that not knowing the date of their patient’s most recent
Td booster would be a major barrier to Tdap vaccination.
This problem may be alleviated somewhat by the ﬂexible
timeframe for Tdap vaccination; the recommendation sug-
gests an interval as short as 2 years since the last Td booster,
and explicitly states that even shorter intervals may be used
[4]. However, it is unclear if physicians will be comfortable
with this abbreviated timeframe. Future clinical trial data is
needed to address issues related to the minimum timeframe
between Td and Tdap administration.
Although our survey did not directly ask about cost-
related issues, 14% of respondents noted cost as a major bar-
rier in an open-ended question on other barriers. Certainly,
cost has been cited previously as a barrier to immunization,
amongbothobstetricians[7]andprimarycareproviders[9].
The extent to which cost will inﬂuence decisions related to
stocking and administering Tdap vaccine is not yet clear. We
cannotsayfromthisstudywhatproportionofobstetricprac-
tices currently stock Td vaccine, which may inﬂuence their
decisionsabouttheTdapvaccine;Tdapcostsabout$20more
than Td per dose.
Amajorityofrespondentstothissurveyfeltthatobstetri-
cians should be involved in promoting Tdap vaccination for
other adults expected to come in close contact with infants.
Thisisentirelyreasonable;duringprenatalcare,obstetricians
have an opportunity to educate prospective parents about
the importance of vaccination for grandparents, childcare
providers, and other close contacts. We found that a slightly
smaller proportion perceived a responsibility to administer
Tdap vaccine, along with other provider groups. These re-
sults are consistent with prior research on other vaccines rec-
ommended for obstetric patients [7]. In practical terms, it is
unrealistic to expect obstetricians to administer a vaccine to
other adults who are not their patients, as there would be sig-
niﬁcant diﬃculties with billing and recordkeeping, as well as
potential concerns regarding liability.
LIMITATIONS
Studies utilizing mailed surveys have inherent limitations.
Response bias may have aﬀected our results. Based on the
limited set of demographic variables available, the only dif-
ference between respondents and nonrespondents was that
respondents were more likely to be board certiﬁed. In addi-
tion, we would expect that our sample is representative of all
US obstetricians within our sampling frame (eg, providing
directpatientcare,nosubspecialtyboardcertiﬁcation),given
that we obtained a random sample from a national physician
database.
We acknowledge that response bias likely exists, but it is
impossible to detect its direction. While it is possible that
those who responded to the survey were more interested in
vaccination issues or had prior clinical experience with per-
tussis, the response rate is comparable to recently published
results from other national, mailed surveys of US obstetri-
cians, on both vaccination-related topics [5, 7]a n dar a n g e
of other obstetric issues [10–13]. In addition, the response
rate is favorable compared to these other studies in that (1)
we were limited to one mailing of the survey, to meet the
timeframe for ACIP deliberations, and (2) it is higher than
the response rates among those obstetricians who were not
part of an established research network [5, 9, 10, 12].
CONCLUSIONS
US obstetricians are likely to agree with the recent national
recommendation to administer Tdap to postpartum moth-
ers and other adults expected to come in close contact with
vulnerable infants. In addition, they would support a recom-
mendation to immunize pregnant women with Tdap, if rec-
ommended by ACIP/ACOG at a later date. However, future
research is needed to assess the extent to which barriers will
impede adoption of new Tdap vaccine recommendations.
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